HCM
IOBT

Hilton Capital Management’s IO Biotech IOBT Stock Holding History

Hilton Capital Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,510
Closed -$15.5K – 147
2025
Q4 		$15.5K Hold
25,510
– – ﹤0.01% 167
2025
Q3 		$9.26K Buy
+25,510
New +$44K ﹤0.01% 172

Other funds holding IOBT

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return

Hilton Capital Management's IOBT Position: Q1 2026 in Review

Hilton Capital Management sold out of IO Biotech (IOBT) in Q1 2026, closing a stake of 25,510 shares — an estimated $15.5K sold.

Hilton Capital Management first reported a position in IOBT in Q3 2025 and held it in 2 quarters. The position peaked at $15.5K in Q4 2025. 12 funds tracked by Wall St. Rank hold IOBT as of Q1 2026.

  • Hilton Capital Management reported no remaining IO Biotech position as of Q1 2026 after selling out during the quarter.
  • Hilton Capital Management sold 25,510 IO Biotech shares in Q1 2026, an estimated $15.5K.
  • Hilton Capital Management first reported a position in IO Biotech in Q3 2025 and held it in 2 quarters.
  • Hilton Capital Management's IO Biotech position peaked at $15.5K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held IO Biotech as of Q1 2026.

Based on Hilton Capital Management's 13F filing for Q1 2026, filed 15 May 2026.